DWTX: Virios Therapeutics Market Cap to Revenue Ratio

Brandmark of Dogwood Therapeutics, Inc. (DWTX)

The market capitalization-to-revenue ratio of Dogwood Therapeutics, Inc. (DWTX) reflects market expectations for the commercialization of nasal treatments for fibromyalgia and the Epstein-Barr virus, while 366.20 captures the current value of the indicator. Steady demand for antiviral drugs renders this sector non-cyclical. Stringent FDA requirements and patent protection create insurmountable barriers to entry for new players, strengthening the company's position.

DWTX Dogwood Therapeutics P/S Multiple (11/08/2026 - 11/18/2026)

Metric breakdowns and analytics for Dogwood Therapeutics, Inc. (DWTX)

Fundamental company analysis:DWTX - Virios Therapeutics
Original product of Virios Therapeutics

For Dogwood Therapeutics, Inc. (DWTX), which is developing innovative fibromyalgia therapy through the suppression of the herpes virus, the P/S multiple serves as a key metric of market value relative to generated revenues. The price-to-sales ratio allows investors to determine the degree of asset overheating by analyzing the divergence of the P/S from its historical average, helping to distinguish the fundamental value of the biotech startup from speculative optimism.